0
Articles |

Sparfloxacin vs Ofloxacin in the Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis : A Multicenter, Double-blind, Randomized, Comparative Study

C. Andrew DeAbate; Dan Henry; George Bensch; Amal Jubran; Sanford Chodosh; Lisa Harper; Diane Tipping; George H. Talbot; Sparfloxacin Multicenter ABECB Study Group
Author and Funding Information

Affiliations: From the Medical Research Center, New Orleans,  From the Foothill Family Clinic, Salt Lake City, Utah,  From the Allergy Immunology Asthma, Inc, Stockton, Calif,  From the Edward Hines, Jr. Veterans Affairs (VA) Hospital/Loyola University of Chicago, Hines, Ill.,  From the VA Outpatient Clinic, Boston,  From the Rhône-Poulenc Rorer Research and Development, Collegeville, Pa.

Affiliations: From the Medical Research Center, New Orleans,  From the Foothill Family Clinic, Salt Lake City, Utah,  From the Allergy Immunology Asthma, Inc, Stockton, Calif,  From the Edward Hines, Jr. Veterans Affairs (VA) Hospital/Loyola University of Chicago, Hines, Ill.,  From the VA Outpatient Clinic, Boston,  From the Rhône-Poulenc Rorer Research and Development, Collegeville, Pa.

Affiliations: From the Medical Research Center, New Orleans,  From the Foothill Family Clinic, Salt Lake City, Utah,  From the Allergy Immunology Asthma, Inc, Stockton, Calif,  From the Edward Hines, Jr. Veterans Affairs (VA) Hospital/Loyola University of Chicago, Hines, Ill.,  From the VA Outpatient Clinic, Boston,  From the Rhône-Poulenc Rorer Research and Development, Collegeville, Pa.

Affiliations: From the Medical Research Center, New Orleans,  From the Foothill Family Clinic, Salt Lake City, Utah,  From the Allergy Immunology Asthma, Inc, Stockton, Calif,  From the Edward Hines, Jr. Veterans Affairs (VA) Hospital/Loyola University of Chicago, Hines, Ill.,  From the VA Outpatient Clinic, Boston,  From the Rhône-Poulenc Rorer Research and Development, Collegeville, Pa.

Affiliations: From the Medical Research Center, New Orleans,  From the Foothill Family Clinic, Salt Lake City, Utah,  From the Allergy Immunology Asthma, Inc, Stockton, Calif,  From the Edward Hines, Jr. Veterans Affairs (VA) Hospital/Loyola University of Chicago, Hines, Ill.,  From the VA Outpatient Clinic, Boston,  From the Rhône-Poulenc Rorer Research and Development, Collegeville, Pa.

Affiliations: From the Medical Research Center, New Orleans,  From the Foothill Family Clinic, Salt Lake City, Utah,  From the Allergy Immunology Asthma, Inc, Stockton, Calif,  From the Edward Hines, Jr. Veterans Affairs (VA) Hospital/Loyola University of Chicago, Hines, Ill.,  From the VA Outpatient Clinic, Boston,  From the Rhône-Poulenc Rorer Research and Development, Collegeville, Pa.

Affiliations: From the Medical Research Center, New Orleans,  From the Foothill Family Clinic, Salt Lake City, Utah,  From the Allergy Immunology Asthma, Inc, Stockton, Calif,  From the Edward Hines, Jr. Veterans Affairs (VA) Hospital/Loyola University of Chicago, Hines, Ill.,  From the VA Outpatient Clinic, Boston,  From the Rhône-Poulenc Rorer Research and Development, Collegeville, Pa.

Affiliations: From the Medical Research Center, New Orleans,  From the Foothill Family Clinic, Salt Lake City, Utah,  From the Allergy Immunology Asthma, Inc, Stockton, Calif,  From the Edward Hines, Jr. Veterans Affairs (VA) Hospital/Loyola University of Chicago, Hines, Ill.,  From the VA Outpatient Clinic, Boston,  From the Rhône-Poulenc Rorer Research and Development, Collegeville, Pa.

Affiliations: From the Medical Research Center, New Orleans,  From the Foothill Family Clinic, Salt Lake City, Utah,  From the Allergy Immunology Asthma, Inc, Stockton, Calif,  From the Edward Hines, Jr. Veterans Affairs (VA) Hospital/Loyola University of Chicago, Hines, Ill.,  From the VA Outpatient Clinic, Boston,  From the Rhône-Poulenc Rorer Research and Development, Collegeville, Pa.

Affiliations: From the Medical Research Center, New Orleans,  From the Foothill Family Clinic, Salt Lake City, Utah,  From the Allergy Immunology Asthma, Inc, Stockton, Calif,  From the Edward Hines, Jr. Veterans Affairs (VA) Hospital/Loyola University of Chicago, Hines, Ill.,  From the VA Outpatient Clinic, Boston,  From the Rhône-Poulenc Rorer Research and Development, Collegeville, Pa.

Affiliations: From the Medical Research Center, New Orleans,  From the Foothill Family Clinic, Salt Lake City, Utah,  From the Allergy Immunology Asthma, Inc, Stockton, Calif,  From the Edward Hines, Jr. Veterans Affairs (VA) Hospital/Loyola University of Chicago, Hines, Ill.,  From the VA Outpatient Clinic, Boston,  From the Rhône-Poulenc Rorer Research and Development, Collegeville, Pa.

Affiliations: From the Medical Research Center, New Orleans,  From the Foothill Family Clinic, Salt Lake City, Utah,  From the Allergy Immunology Asthma, Inc, Stockton, Calif,  From the Edward Hines, Jr. Veterans Affairs (VA) Hospital/Loyola University of Chicago, Hines, Ill.,  From the VA Outpatient Clinic, Boston,  From the Rhône-Poulenc Rorer Research and Development, Collegeville, Pa.


Affiliations: From the Medical Research Center, New Orleans,  From the Foothill Family Clinic, Salt Lake City, Utah,  From the Allergy Immunology Asthma, Inc, Stockton, Calif,  From the Edward Hines, Jr. Veterans Affairs (VA) Hospital/Loyola University of Chicago, Hines, Ill.,  From the VA Outpatient Clinic, Boston,  From the Rhône-Poulenc Rorer Research and Development, Collegeville, Pa.

1998 by the American College of Chest Physicians


Chest. 1998;114(1):120-130. doi:10.1378/chest.114.1.120
Text Size: A A A
Published online

Abstract

Study objective: Comparison of efficacy and safety of sparfloxacin vs ofloxacin for treatment of acute bacterial exacerbations of chronic bronchitis (ABECB).

Design: Multicenter, double-blind, randomized study.

Setting: Sixty-eight private offices and outpatient clinics in the United States and Canada.

Patients: Seven hundred ninety-eight adults with ABECB, as confirmed by the acute onset of new (or worsened from the immediate premorbid state) cough and sputum production.

Interventions: Randomization 1:1 to sparfloxacin, 400 mg on day 1, then 200 mg once daily, or ofloxacin, 400 mg twice daily, with matching comparator placebos, given concurrently for 10 consecutive days.

Results: The primary efficacy parameter was overall response in the bacteriologically evaluable population. Overall success rates in this population were 85.3% and 89.3% for sparfloxacin and ofloxacin, respectively. The two-sided 95% confidence interval was −9.9, 1.9, indicating that sparfloxacin was statistically equivalent to ofloxacin. The all-treated population analysis was similar to that in the evaluable population. Bacterial eradication rates were similar in both treatment groups for Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, Chlamydia pneumoniae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Enterobacter cloacae, and Staphylococcus aureus. The frequency of adverse events overall was comparable in the two treatment groups. The sparfloxacin group had a lower frequency of digestive and nervous system adverse events, but a higher frequency of photosensitivity reactions than the ofloxacin group.

Conclusions: Once-daily oral treatment with 200 mg sparfloxacin (after initial 400 mg dose) is as effective as twice-daily treatment with 400 mg ofloxacin in patients with ABECB.


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543